ArticleScientific reports2025
Impact of pulmonary infection and antibiotic use on recurrent myocardial infarction in patients with myocardial infarction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the impact of pulmonary infections and antibiotic use on the recurrence of myocardial infarction (MI) in patients. A total of 3807 MI patients were included in this study. The effects of pulmonary infections and different antibiotics on recurrent MI were investigated using multivariable logistic regression and propensity score matching (PSM) analysis. Kaplan-Meier survival curves were used to compare the risk of recurrent MI between patients with and without pulmonary infections. In the multivariable logistic regression analysis, pulmonary infections significantly increased the risk of recurrent MI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) (odds ratio [OR] = 1.47, 95% confidence interval [CI]: 1.22-1.79, P < 0.0001) and ST-segment elevation myocardial infarction (STEMI) (OR = 1.43, 95% CI: 1.15-1.80, P = 0.0016). PSM analysis showed that, without adjusting for antibiotic use, pulmonary infections significantly increased the risk of recurrent MI (NSTEMI: OR = 1.41, 95% CI: 1.12-1.79, P = 0.004; STEMI: OR = 1.48, 95% CI: 1.13-1.95, P = 0.0051). However, after adjusting for antibiotic use, the impact of pulmonary infections on recurrent MI was no longer significant (NSTEMI: OR = 0.91, 95% CI: 0.57-1.45, P = 0.691; STEMI: OR = 1.06, 95% CI: 0.80-1.41, P = 0.6925). Different antibiotics had significant effects on the risk of recurrent MI: quinolone antibiotics were associated with an increased risk, while cephalosporin antibiotics and metronidazole were associated with a decreased risk. Pulmonary infections significantly increase the risk of recurrent MI in patients, and antibiotic use can modify this effect. Clinically, the use of antibiotics and management of pulmonary infections should be carefully considered to optimize treatment strategies for MI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.